(DMP) Dermapharm Holding SE - Overview
Stock: Branded Generics, OTC, Supplements, Dermatology, Imports
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 2.59% |
| Yield on Cost 5y | 1.75% |
| Yield CAGR 5y | 0.56% |
| Payout Consistency | 87.1% |
| Payout Ratio | 78.3% |
| Risk 5d forecast | |
|---|---|
| Volatility | 27.7% |
| Relative Tail Risk | -13.8% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.22 |
| Alpha | -9.77 |
| Character TTM | |
|---|---|
| Beta | 0.117 |
| Beta Downside | 0.208 |
| Drawdowns 3y | |
|---|---|
| Max DD | 36.16% |
| CAGR/Max DD | 0.05 |
Description: DMP Dermapharm Holding SE January 14, 2026
Dermapharm Holding SE (XETRA:DMP) manufactures and distributes off-patent branded pharmaceuticals across Germany, France, Spain, Austria, Switzerland and other markets. Its business is split into three segments: Branded Pharmaceuticals (generic and branded-generic drugs), Other Healthcare Products (OTC, vitamins, minerals, food supplements, cosmetics and medical devices), and a Parallel Import Business that brings originator medicines into the EU under the Axicorp brand. Core product families include Dekristol, Keltican, Tromcardin, Ketozolin, Bite Away and Herpotherm, covering therapeutic areas such as dermatology, allergology, pain & inflammation, cardiovascular health, gynecology and urology.
Key drivers for Dermapharm’s performance include the steady growth of the European generics market-projected to expand at ~4 % CAGR through 2028-combined with strong demand for OTC and nutraceuticals, which have higher margin potential than pure generics. The company’s 2023 EBITDA margin of roughly 12 % reflects efficient cost control, while its exposure to the euro-dollar exchange rate adds a modest currency risk to international sales. A recent strategic focus on expanding its parallel-import portfolio could improve pricing flexibility, but it also hinges on regulatory approval cycles and competitive pressure from larger multinational players.
For a deeper, data-driven assessment of Dermapharm’s valuation and risk profile, you may find the analytical tools on ValueRay worth exploring.
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income: 116.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA 0.78 > 1.0 |
| NWC/Revenue: 30.24% < 20% (prev 21.41%; Δ 8.83% < -1%) |
| CFO/TA 0.09 > 3% & CFO 186.3m > Net Income 116.0m |
| Net Debt (864.3m) to EBITDA (311.7m): 2.77 < 3 |
| Current Ratio: 2.20 > 1.5 & < 3 |
| Outstanding Shares: last quarter (53.8m) vs 12m ago -0.11% < -2% |
| Gross Margin: 58.96% > 18% (prev 0.40%; Δ 5856 % > 0.5%) |
| Asset Turnover: 54.72% > 50% (prev 54.59%; Δ 0.14% > 0%) |
| Interest Coverage Ratio: 3.92 > 6 (EBITDA TTM 311.7m / Interest Expense TTM 57.2m) |
Altman Z'' 2.93
| A: 0.17 (Total Current Assets 643.4m - Total Current Liabilities 292.6m) / Total Assets 2.12b |
| B: 0.23 (Retained Earnings 479.0m / Total Assets 2.12b) |
| C: 0.11 (EBIT TTM 224.2m / Avg Total Assets 2.12b) |
| D: 0.37 (Book Value of Equity 548.4m / Total Liabilities 1.47b) |
| Altman-Z'' Score: 2.93 = A |
Beneish M -3.31
| DSRI: 1.06 (Receivables 131.1m/123.0m, Revenue 1.16b/1.16b) |
| GMI: 0.67 (GM 58.96% / 39.71%) |
| AQI: 0.98 (AQ_t 0.55 / AQ_t-1 0.56) |
| SGI: 1.00 (Revenue 1.16b / 1.16b) |
| TATA: -0.03 (NI 116.0m - CFO 186.3m) / TA 2.12b) |
| Beneish M-Score: -3.31 (Cap -4..+1) = AA |
What is the price of DMP shares?
Over the past week, the price has changed by +4.30%, over one month by -6.56%, over three months by +9.32% and over the past year by -4.56%.
Is DMP a buy, sell or hold?
What are the forecasts/targets for the DMP price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 47 | 29.3% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 36.8 | 1.2% |
DMP Fundamental Data Overview February 02, 2026
P/E Trailing = 16.9095
P/E Forward = 16.4474
P/S = 1.598
P/B = 2.9274
Revenue TTM = 1.16b EUR
EBIT TTM = 224.2m EUR
EBITDA TTM = 311.7m EUR
Long Term Debt = 933.4m EUR (from longTermDebt, last quarter)
Short Term Debt = 77.5m EUR (from shortTermDebt, last quarter)
Debt = 1.01b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 864.3m EUR (from netDebt column, last quarter)
Enterprise Value = 2.68b EUR (1.81b + Debt 1.01b - CCE 146.6m)
Interest Coverage Ratio = 3.92 (Ebit TTM 224.2m / Interest Expense TTM 57.2m)
EV/FCF = 18.56x (Enterprise Value 2.68b / FCF TTM 144.2m)
FCF Yield = 5.39% (FCF TTM 144.2m / Enterprise Value 2.68b)
FCF Margin = 12.43% (FCF TTM 144.2m / Revenue TTM 1.16b)
Net Margin = 10.00% (Net Income TTM 116.0m / Revenue TTM 1.16b)
Gross Margin = 58.96% ((Revenue TTM 1.16b - Cost of Revenue TTM 476.1m) / Revenue TTM)
Gross Margin QoQ = 36.44% (prev 67.66%)
Tobins Q-Ratio = 1.26 (Enterprise Value 2.68b / Total Assets 2.12b)
Interest Expense / Debt = 1.45% (Interest Expense 14.7m / Debt 1.01b)
Taxrate = 25.47% (14.1m / 55.2m)
NOPAT = 167.1m (EBIT 224.2m * (1 - 25.47%))
Current Ratio = 2.20 (Total Current Assets 643.4m / Total Current Liabilities 292.6m)
Debt / Equity = 1.56 (Debt 1.01b / totalStockholderEquity, last quarter 649.2m)
Debt / EBITDA = 2.77 (Net Debt 864.3m / EBITDA 311.7m)
Debt / FCF = 6.00 (Net Debt 864.3m / FCF TTM 144.2m)
Total Stockholder Equity = 625.1m (last 4 quarters mean from totalStockholderEquity)
RoA = 5.47% (Net Income 116.0m / Total Assets 2.12b)
RoE = 18.56% (Net Income TTM 116.0m / Total Stockholder Equity 625.1m)
RoCE = 14.38% (EBIT 224.2m / Capital Employed (Equity 625.1m + L.T.Debt 933.4m))
RoIC = 15.01% (NOPAT 167.1m / Invested Capital 1.11b)
WACC = 4.46% (E(1.81b)/V(2.82b) * Re(6.35%) + D(1.01b)/V(2.82b) * Rd(1.45%) * (1-Tc(0.25)))
Discount Rate = 6.35% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 0.0 | Cagr: 0.0%
[DCF Debug] Terminal Value 87.02% ; FCFF base≈137.7m ; Y1≈148.0m ; Y5≈180.8m
Fair Price DCF = 83.34 (EV 5.35b - Net Debt 864.3m = Equity 4.49b / Shares 53.8m; r=5.90% [WACC]; 5y FCF grow 8.36% → 2.90% )
EPS Correlation: -19.88 | EPS CAGR: -10.49% | SUE: 0.00 | # QB: 0
Revenue Correlation: 55.14 | Revenue CAGR: 2.11% | SUE: 0.03 | # QB: 0
EPS next Year (2026-12-31): EPS=2.54 | Chg30d=+0.000 | Revisions Net=+1 | Growth EPS=+10.7% | Growth Revenue=+4.0%